Sign in to view content

1-Year Results of a Phase 2 Pharmacodynamic Study: Subretinal Delivery of Investigational Gene Therapy ABBV-RGX-314 for Neovascular AMD

Robert L. Avery, MD

Video
Published 2025

Related

Episode 4: 3-year Results of the TREX-AMD Trial with Dr. Charles Wykoff
Keyvan Koushan, MD, FRCSC
Member Podcasts
2017
Comparison of CRISPR-based Genome Editing of VEGF-A as Treatment Strategy for Choroidal Neovascularization
Glenn C. Yiu, MD, PhD
Updates from the Field
2019
20+ Years of The DRCR Network: What We Have Learned About Diabetic Retinopathy
John W. Kitchens, MD
Updates from the Field
2025

Category: AMD-Neovascular

See more